EUVIMEDEUVIMED entdecken
Open Access

Study of fingolimod, nitric oxide inhibitor, and P-glycoprotein inhibitor in modulating the P-glycoprotein expression via an endothelin–sphingolipid pathway in an animal model of pharmacoresistant epilepsy

Nitika Garg, Rupa Joshi, Alka Bhatia, Seema Bansal, Amitava Chakrabarti, Ajay Prakash, Biman Saikia, Manish Modi, Bikash Medhi

Indian Journal of Pharmacology · 2023

DOI: 10.4103/ijp.ijp_100_23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Pharmacology, 2023. Verfasst von Nitika Garg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Fingolimod Hydrochloride. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The overexpression of P-glycoprotein (P-gp) contributes to drug resistance in patients with epilepsy, and the change of P-gp expression located at the blood–brain barrier alienates the anti-seizure effects of P-gp substrates. Thus, the present study explored the effect of fingolimod (FTY720) acting through an endothelin–sphingolipid pathway on P-gp-induced pentylenetetrazol (PTZ)-kindled phenobarbital (PB)-resistant rats. MATERIALS AND METHODS: PTZ kindling (30 mg/kg; i.p.) and PB (40 mg/kg; orally) were used to develop an animal model of refractory epilepsy. The effect of Fingolimod on seizure score (Racine scale), plasma and brain levels of PB (high-performance liquid chromatography), and blood–brain barrier permeability (Evans blue dye) was determined. Further, Fingolimod's neuroprotective effect was determined by measuring the levels of various inflammatory cytokines, oxidative stress parameters, and neurotrophic factors in rat brain homogenate. The Fingolimod's effect on P-gp expression was estimated by reverse transcriptase–polymerase chain reaction and immunohistochemistry in rat brain. The H and E staining was done to determine the neuronal injury. RESULTS: Fingolimod significantly ( P < 0.001) reduced the seizure score in a dose-dependent manner and alleviated the blood–brain barrier permeability. It decreased the P-gp expression, which further increased the brain PB concentration. Fingolimod significantly ( P < 0.01) reduced oxidative stress as well as inflammation. Moreover, it attenuated the raised neuronal injury score in a resistant model of epilepsy. CONCLUSION: The modulation of the P-gp expression by Fingolimod improved drug delivery to the brain in an animal model of refractory epilepsy. Therefore, S1P signaling could serve as an additional therapeutic target to overcome refractoriness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyFingolimod HydrochlorideAnimalsHumansRatsAnticonvulsantsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1EndothelinsModels, AnimalNitric OxidePentylenetetrazoleSeizuresSphingolipids

Stichwörter der Autor:innen

FingolimodP-glycoproteinneuroprotectionphenobarbital resistancerefractory epilepsy

Substanzen

AnticonvulsantsATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1EndothelinsFingolimod HydrochlorideNitric OxidePentylenetetrazoleSphingolipids

Autor:innen und Institutionen

  • Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.
  • Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh; Department of Pharmacology, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to b…
  • Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.
  • Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh; Department of Pharmacology, MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be university), Mullana,…
  • Department of Immunopathology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.
  • Department of Neurology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, Haryana, India.

Zitieren

APA

Garg, N., Joshi, R., Bhatia, A., Bansal, S., Chakrabarti, A., Prakash, A., Saikia, B., Modi, M., & Medhi, B. (2023). Study of fingolimod, nitric oxide inhibitor, and P-glycoprotein inhibitor in modulating the P-glycoprotein expression via an endothelin–sphingolipid pathway in an animal model of pharmacoresistant epilepsy. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_100_23

Vancouver

Garg N, Joshi R, Bhatia A, Bansal S, Chakrabarti A, Prakash A, et al. Study of fingolimod, nitric oxide inhibitor, and P-glycoprotein inhibitor in modulating the P-glycoprotein expression via an endothelin–sphingolipid pathway in an animal model of pharmacoresistant epilepsy. Indian Journal of Pharmacology. 2023. doi:10.4103/ijp.ijp_100_23

BibTeX
@article{Garg2023,
  author = {Garg, Nitika and Joshi, Rupa and Bhatia, Alka and Bansal, Seema and Chakrabarti, Amitava and Prakash, Ajay and Saikia, Biman and Modi, Manish and Medhi, Bikash},
  title = {Study of fingolimod, nitric oxide inhibitor, and P-glycoprotein inhibitor in modulating the P-glycoprotein expression via an endothelin–sphingolipid pathway in an animal model of pharmacoresistant epilepsy},
  journal = {Indian Journal of Pharmacology},
  year = {2023},
  doi = {10.4103/ijp.ijp_100_23}
}
Kostenlos starten →